StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →6-factor scoring with sector-relative rank. Updated daily.
Each row shows where TMO sits in our scored universe today on a single observational measurement. P85 means TMO ranks above 85% of peers on that factor right now. Percentile rankings are descriptive — they are not buy/sell signals or quality judgments. Universe refreshed every 60 seconds.
Today's volume vs prior session average.
Absolute daily price move vs peers.
24h article count relative to the universe.
AI-classified polarity of recent news.
Today's dollar turnover (volume × VWAP).
Signed daily return vs the rest of the universe.
Stonvex publishes percentile measurements as observational data only. Nothing here constitutes a recommendation, prediction, or advice about whether to buy, sell, or hold any security. Stonvex is not a registered investment advisor.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-22 | $446.80 | $448.28 | +0.33% | 1.7M |
| 05-26 | $447.36 | $448.18 | +0.18% | 1.9M |
| 05-27 | $449.93 | $456.21 | +1.40% | 3.0M |
| 05-28 | $461.25 | $487.22 | +5.63% | 4.4M |
| 05-29 | $482.17 | $492.51 | +2.14% | 4.2M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Aggregate of 34 sell-side ratings as of 2026-05-01. Stonvex does not endorse these ratings.
Earnings (▲ beat / ▼ miss) and ex-dividend dates plotted on the price line. Educational — proximity does not establish causation.
Next report date, year-over-year trend, and recent quarter history.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q3 2026 (Est.) Expected 2026-07-21 | Q1 2026 2026-03-28 | Annual 2025 2025-12-31 | Q3 2025 2025-09-27 | Q2 2025 2025-06-28 |
|---|---|---|---|---|---|
Revenue | $11.82B | $11.01B | $44.56B | $32.34B | $21.22B |
Operating Income | Not available | $1.86B | $7.75B | $5.49B | $3.55B |
Net Income | Not available | $1.65B | $6.70B | $4.74B | $3.12B |
EPS (Diluted) | $5.77 | $4.43 | $17.74 | $12.53 | $8.26 |
Total Assets | Not available | $113.28B | $110.34B | $103.02B | $101.23B |
Total Liabilities | Not available | Not available | Not available | Not available | Not available |
Cash & Equivalents | Not available | $3.25B | $9.85B | $1.98B | $4.58B |
Free Cash Flow OCF − CapEx | Not available | $816.00M | $6.29B | $3.30B | $1.47B |
Shares Outstanding | Not available | 373.00M | 378.00M | 378.00M | 378.00M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Each factor shows TMO's percentile within the scored universe — observational ranking, not a recommendation.
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.